TEVA Stock Analysis: Buy, Sell, or Hold?
TEVA - Teva Pharmaceutical Industries Limited American Depositary Shares
$31.82
-0.36 (-1.12%)
▼
5d:
-8.17%
30d:
-7.93%
90d:
+2.15%
HOLD
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Jul 29, 2026
13d
Get Alerted When TEVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TEVA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: TEVA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$64.15
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$39.83
20.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TEVA is currently trading at $31.82, which is considered oversold relative to its 30-day fair value range of $32.54 to $34.41. The stock's valuation (Forward PE: 10.3) is in line with its historical norms (10.7). Remarkably, the market is currently pricing in an annual earnings decline of 1.3% over the next few years. This pessimistic expectation contrasts with the company's recent 72.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, TEVA is in a uptrend. The price is currently testing key support at $31.66. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TEVA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $40.90 (+28.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TEVA is in a uptrend. The price is currently testing key support at $31.66. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TEVA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $40.90 (+28.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$32.54 -
$34.41
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.5% below Wall St target ($40.90)
- CAUTION: 5-day price weakness (-8.2%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$32.54 -
$34.41
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$31.66
Resistance Level
$35.47
Current Trend
Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.34
Wall Street Target
$40.90
(+28.5%)
Revenue Growth (YoY)
2.3%
Earnings Growth (YoY)
72.2%
Profit Margin
9.0%
Valuation Discount vs History
-1.3% cheaper
PE vs Historical
10.3 vs 10.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.3%
(market-implied from PE analysis)
1-Year Target
$31.41
(-1%)
2-Year Target
$31.00
(-3%)
3-Year Target
$30.60
(-4%)
3-Yr Target (if PE normalizes)
(PE: 10→11)
$31.67
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 38.9%)
$179.81
(+465%)
Base:
(SPY PE: 10.3, Growth: 38.9%)
$85.33
(+168%)
Bear:
(PE: 8.8, Growth: 38.9%)
$72.53
(+128%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 24.59 | Current EPS (TTM): $1.34
Bull Case
$72.49
(+128%)
Analyst growth 100.0%, PE expands to 27.1
Base Case
$65.90
(+107%)
Market implied 100.0%, PE stable at 24.6
Bear Case
$22.41
(-30%)
Severe decline -20.0%, PE contracts to 20.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.3 to 10.7
Stabilization Target:
$32.94
(+3.5%)
PE Expansion Potential:
+3.5%
Share & Embed Analysis
Last updated: July 14, 2026 8:11 PM ET
Data refreshes hourly during market hours. Next update: 9:11 PM
Data refreshes hourly during market hours. Next update: 9:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TEVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Mark Sabag
SELL
62102 shares
2026-03-17
Brian Savage
SELL
1127 shares
2026-03-05
Christine Fox
SELL
7924 shares
2026-03-05
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 54 HOLD |
